Infinity Pharma (INFI) – Hot FDA News
-
Infinity Pharma (INFI) Announces IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study
-
Infinity Pharma (INFI) & Bristol-Myers Squibb Report Expansion of Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab)
Back to INFI Stock Lookup
